Literature DB >> 33397733

Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.

Joshua F Baker1,2, Bryant R England3,4, Michael George2, Grant Cannon5, Brian Sauer6,7, Alexis Ogdie2, Bartlett C Hamilton8, Carlos Hunter9, Michael J Duryee10, Geoffrey Thiele11,12, Ted R Mikuls13.   

Abstract

PURPOSE: Rheumatoid arthritis (RA) is associated with a higher risk of diabetes mellitus (DM). Our aim was to determine associations between inflammatory disease activity (including evaluation of specific cytokines and chemokines) and incident DM.
METHODS: Participants were adults with physician-confirmed RA from Veteran's Affairs Rheumatoid Arthritis Registry. Disease activity and clinical assessments occur longitudinally as part of clinical care. Thirty cytokines and chemokines were measured in banked serum obtained at the time of enrolment. Cytokine/chemokine values were log-adjusted and standardised (per SD). Incident DM was defined based on validated algorithms using diagnostic codes and medications. Multivariable Cox proportional hazard models evaluated associations between clinical factors and incident DM. Independent associations between cytokines/chemokines and incident DM were assessed adjusting for age, sex, race, smoking, body mass index (BMI) and medication use at baseline.
RESULTS: Among 1866 patients with RA without prevalent DM at enrolment, there were 130 incident cases over 9223 person-years of follow-up. High Disease Activity Score (DAS28)-C reactive protein (CRP), obese BMI, older age and male sex were associated with greater risk for incident DM while current smoking and methotrexate use were protective. Patients using methotrexate were at lower risk. Several cytokines/chemokines evaluated were independently associated (per 1 SD) with DM incidence including interleukin(IL)-1, IL-6 and select macrophage-derived cytokines/chemokines (HR range 1.11-1.26). These associations were independent of the DAS28-CRP.
CONCLUSIONS: Higher disease activity and elevated levels of cytokines/chemokines are associated with a higher risk of incident DM in patients with RA. Future study may help to determine if targeted treatments in at-risk individuals could prevent the development of DM. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arthritis; epidemiology; inflammation; rheumatoid

Mesh:

Substances:

Year:  2021        PMID: 33397733      PMCID: PMC8928597          DOI: 10.1136/annrheumdis-2020-219140

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis.

Authors:  K Perdan-Pirkmajer; S Pirkmajer; M Thevis; A Thomas; S Praprotnik; A Hočevar; Ž Rotar; N Gašperšič; S Sodin-Šemrl; J Žibert; J Omersel; A V Chibalin; M Tomšič; A Ambrožič
Journal:  Scand J Rheumatol       Date:  2016-01-04       Impact factor: 3.641

Review 2.  Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus.

Authors:  Maggie S Burhans; Derek K Hagman; Jessica N Kuzma; Kelsey A Schmidt; Mario Kratz
Journal:  Compr Physiol       Date:  2018-12-13       Impact factor: 9.090

3.  Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.

Authors:  Lisa A Davis; Grant W Cannon; Lauren F Pointer; Leah M Haverhals; Roger K Wolff; Ted R Mikuls; Andreas M Reimold; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Robert Valuck; Allan Prochazka; Liron Caplan
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

4.  Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry.

Authors:  Ted R Mikuls; Brian T Fay; Kaleb Michaud; Harlan Sayles; Geoffrey M Thiele; Liron Caplan; Dannette Johnson; John S Richards; Gail S Kerr; Grant W Cannon; Andreas Reimold
Journal:  Rheumatology (Oxford)       Date:  2010-07-21       Impact factor: 7.580

5.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.

Authors:  Daniel H Solomon; Elena Massarotti; Rajesh Garg; Jun Liu; Claire Canning; Sebastian Schneeweiss
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

6.  Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.

Authors:  Brendan M Everett; Marc Y Donath; Aruna D Pradhan; Tom Thuren; Prem Pais; Jose C Nicolau; Robert J Glynn; Peter Libby; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2018-03-12       Impact factor: 24.094

Review 7.  Diabetes mellitus and inflammation.

Authors:  Eric Lontchi-Yimagou; Eugene Sobngwi; Tandi E Matsha; Andre Pascal Kengne
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

8.  Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes.

Authors:  Katherine Samaras; Natalia K Botelho; Donald J Chisholm; Reginald V Lord
Journal:  Obesity (Silver Spring)       Date:  2009-12-17       Impact factor: 5.002

9.  Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Authors:  Siri Lillegraven; Jeffrey D Greenberg; George W Reed; Katherine Saunders; Jeffrey R Curtis; Leslie Harrold; Marc C Hochberg; Dimitrios A Pappas; Joel M Kremer; Daniel H Solomon
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

10.  Identifying diabetes cases from administrative data: a population-based validation study.

Authors:  Lorraine L Lipscombe; Jeremiah Hwee; Lauren Webster; Baiju R Shah; Gillian L Booth; Karen Tu
Journal:  BMC Health Serv Res       Date:  2018-05-02       Impact factor: 2.655

View more
  4 in total

Review 1.  Mechanistic and therapeutic links between rheumatoid arthritis and diabetes mellitus.

Authors:  Jing Li; Yazhuo Chen; Qingyun Liu; Zhufang Tian; Yan Zhang
Journal:  Clin Exp Med       Date:  2022-03-20       Impact factor: 3.984

Review 2.  Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.

Authors:  Marco Infante; Nathalia Padilla; Rodolfo Alejandro; Massimiliano Caprio; David Della-Morte; Andrea Fabbri; Camillo Ricordi
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

3.  Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study.

Authors:  So Hye Nam; Minju Kim; Ye-Jee Kim; Soo Min Ahn; Seockchan Hong; Chang-Keun Lee; Bin Yoo; Ji-Seon Oh; Yong-Gil Kim
Journal:  J Clin Med       Date:  2022-04-10       Impact factor: 4.964

4.  Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.

Authors:  Tate M Johnson; Harlan R Sayles; Joshua F Baker; Michael D George; Punyasha Roul; Cheng Zheng; Brian Sauer; Katherine P Liao; Daniel R Anderson; Ted R Mikuls; Bryant R England
Journal:  Ann Rheum Dis       Date:  2021-05-28       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.